Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

Revenue projections:

Revenue projections for APLLTD
Revenue projections for APLLTD

Alembic Pharmaceuticals Limited's revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 20.105835
debtToEquity 24.232000
earningsGrowth 0.148000
revenueGrowth 0.095000
grossMargins 0.722320
operatingMargins 0.121340
trailingEps 30.680000
forwardEps 43.500000

APLLTD's Forward PE ratio suggests that the stock is priced appropriately in relation to its earnings. Not being overpriced, it offers room for growth, signaling potential upside for investors looking for a stock with reasonable valuation and growth potential.
APLLTD's low Debt-to-Equity ratio demonstrates that the company is not over-leveraged. This means it maintains a healthy balance between debt and equity, lowering financial risk and contributing to overall financial stability, which could attract risk-averse investors.
APLLTD's forward EPS exceeds its trailing EPS, indicating that the company is projected to be more profitable in the current financial year compared to the previous one. This suggests positive growth and improved earnings, signaling an optimistic outlook for APLLTD's financial performance.

Price projections:

Price projections for APLLTD
Price projections for APLLTD

APLLTD's price has consistently remained near the lower edge of projections, suggesting that it is not fully meeting market expectations. This could indicate a need for improved performance or strategies to boost investor confidence.

Insider Transactions:

Insider Transactions for APLLTD
Insider Transactions for APLLTD


APLLTD saw 20 buying transactions, each while market price hovered at 881.7800018310547.No buy transactions occurred during the period under consideration.APLLTD's current price levels are marked by increased selling, which could indicate further price drops. If this selling trend persists, the stock may continue to decline as investor confidence weakens.

Recommendation changes over time:

Recommendations trend for APLLTD
Recommendations trend for APLLTD


Analysts have been favoring Alembic Pharmaceuticals Limited with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning Alembic Pharmaceuticals Limited as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.